Aptevo Therapeutics Inc. (NASDAQ:APVO) Short Interest Up 18.7% in March

Aptevo Therapeutics Inc. (NASDAQ:APVO) was the recipient of a large increase in short interest in March. As of March 31st, there was short interest totalling 34,300 shares, an increase of 18.7% from the March 15th total of 28,900 shares. Based on an average daily volume of 122,800 shares, the days-to-cover ratio is presently 0.3 days. Approximately 5.1% of the shares of the stock are sold short.

Institutional Investors Weigh In On Aptevo Therapeutics

Hedge funds have recently modified their holdings of the company. Dimensional Fund Advisors LP acquired a new stake in shares of Aptevo Therapeutics during the 4th quarter valued at $29,000. Virtu Financial LLC acquired a new stake in shares of Aptevo Therapeutics during the 2nd quarter valued at $46,000. Citadel Advisors LLC bought a new position in Aptevo Therapeutics during the 3rd quarter worth $51,000. Bank of New York Mellon Corp bought a new position in Aptevo Therapeutics during the 1st quarter worth $152,000. Finally, Renaissance Technologies LLC raised its position in Aptevo Therapeutics by 18.7% during the 2nd quarter. Renaissance Technologies LLC now owns 69,886 shares of the biotechnology company’s stock worth $250,000 after purchasing an additional 11,000 shares during the last quarter. Institutional investors and hedge funds own 8.06% of the company’s stock.

Aptevo Therapeutics Stock Down 7.3 %

Shares of APVO stock opened at $0.78 on Tuesday. The stock’s fifty day moving average price is $5.15 and its two-hundred day moving average price is $8.05. Aptevo Therapeutics has a fifty-two week low of $0.76 and a fifty-two week high of $91.96.

Analyst Upgrades and Downgrades

Separately, StockNews.com assumed coverage on Aptevo Therapeutics in a report on Wednesday, April 10th. They issued a “hold” rating on the stock.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company's lead clinical candidates are APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndromes; and.